Leukemia Cancer Studies Currently Recruiting Participants at the University of Chicago Medicine Comprehensive Cancer Center

Study Number Title
10-064-B Molecular characterization of hematopoietic malignancies
Select
12-1959 Initial Phase 1 Study of WT2725 Dosing Emulsion in Patients with Advanced Malignancies
Select
IRB14-0702 A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)
Select
IRB14-0881 A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia with 17p Deletion
Select
IRB14-1538 The Life After Stopping Tyrosine Kinase Inhibitors Study
Select
IRB14-0059 A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Select
6492
Select
16070A A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
Select
10-617-A COG AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)
Select
12-2179 A Phase 1/2, Open-label, Dose-escalation, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered NS-018 in Patients with Primary Myelofibrosis, Post polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis
Select
16840A E2905: Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in Combination with Epoetin Alfa (Procrit®) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Select
IRB14-0381 E1912: A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
Select
CIRB14-1502 AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
4186 Etiology Of Alkylator-Induced Myeloid Leukemia
Select
12-0153 A phase 1b study to evaluate the safety and preliminary efficacy of PF-04449913, an oral hedgehog inhibitor, in combination with intensive chemotherapy, low dose ara-C or decitabine in patients with acute myeloid leukemia or high risk myelodysplastic syndrome.
Select
IRB14-0119 A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (Sine) Selinexor (Kpt-330) Versus Specified Physician’s Choice in Patients = 60 Years Old With Relapsed/Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation
Select
10-586-A COG AALL08B1 Classification of Newly Diagnosed Acute Lymphoblastic Leukemia
Select
12-1588 COG AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum
Select
16139B A Randomized Phase II Study of Oral Sapacitabine in Elderly Patients with Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndromes.
Select
IRB14-0076 A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation
Select
IRB14-1076 Phase I Study of an Oncofetal Antigen (“OFA”) Multi-Peptide Immunotherapy (“BB-MPI-03”) in Subjects with Hematologic Cancer
Select
IRB14-0651 A Phase 1b Study of ABT-199 (GDC-0199) in Combination with Azacitidine or Decitabine in Treatment Naïve Subjects with Acute Myelogenous Leukemia Who Are = 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy
Select
IRB14-1567 A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy
IRB13-0716 Monitoring tyrosine kinase inhibitors (TKI) response in chronic myeloid leukemia (CML) patients by longitudinal collection and evaluation of 'omics' data
Select
12-0111 Phase I investigation of the feasibility of combining 5-azacytidine with highdose cytarabine (HiDAC) and mitoxantrone chemotherapy in a sequential manner for remission induction in high-risk acute myelogenous leukemia (AML)
Select
12-2245 An Open-label Extension Study in Patients 65 Years or Older with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 versus Chlorambucil)
Select
IRB13-0858 A Phase I Study of L-asparaginase Encapsulated in Red Blood Cells (ERYASP) in Combination with the CALGB Regimen During Induction and Consolidation Phases for Frontline Therapy of Subjects Older than 40 Years with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
Select
IRB14-0085 A Phase II, Randomized Trial of Standard of Care, With or Without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia
Select
IRB14-0331 A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 in Subjects with Myelodysplastic Syndrome after Treatment with Hypomethylating Agents
Select
IRB13-1177 A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Select
IRB13-0360 S1203: A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Select
IRB13-1440 A041202: A Randomized Phase III Study of Bendamustine plus Rituximab plus Rituximab versus Ibrutinib plus Ritaximab versus Ibrutinib Alone In Untreated Older Patients (>65 years of age) with Chronic Lymphocytic Leukemia (CLL)
09-130-B A University of Chicago Leukemia Registry Protocol.
11-0014 Evaluation of patients with hematopoietic malignancies and their family members for mutations in RUNX1, CEBPA, and p53.
Select
10-583-A AML08: A Phase III Randomized Trial of Clofarabine, Plus Cytarabine Versus Conventional Induction Therapy and a Phase III Study of Natural Killer Cell Transplantation in Patients With Newly Diangosed Acute Myeloid Leukemia
Select
IRB13-0405 CAMN107AUS37A - Phase II Randomized, Multicenter Study of Treatment-free Remission in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients Who Achieve and Sustain MR4.5 After Switching to Nilotinib (Tasigna)
Select
CIRB14-1100 E1910: A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Select
11-0650 An open label, multicenter, phase II study to evaluate efficacy and safety of the BiTE antibody blinatumomab in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)
Select
CIRB14-1184 COG AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
Select
IRB13-0915 NCI 9443: A Phase II Study of MEK 1/2 Inhibitor GSK212 (Trametinib) in Combination with AKT Inhibitor GSK795 in Acute Myeloid Leukemia (AML) with RAS Mutation

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.
Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT team